timothy sykes logo
Haemonetics Stock Climbs As Analysts Hike Price Targets Thumbnail
G Google News

Haemonetics Stock Climbs As Analysts Hike Price Targets

JACK KELLOGG•UPDATED AUG. 18, 2026, 4:47 PM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Haemonetics Corporation stocks have been trading up by 15.77 percent following upbeat sentiment around its latest business performance.

Key Takeaways

  • Haemonetics beat fiscal Q1 expectations on both EPS and revenue, gained plasma market share, kept Blood Management Technologies strong, returned Interventional Technologies to growth, and raised full-year guidance.
  • The company posted fiscal Q1 adjusted EPS of $1.14 versus $0.87 expected, and net revenue of $339.4M versus the $327.9M FactSet consensus.
  • Haemonetics modestly raised its FY27 guidance, lifting adjusted EPS and revenue growth outlooks to 5%-8% from 4%-7%.
  • Bank of America, Raymond James, Baird, and Barrington Research all raised price targets on Haemonetics and reiterated Buy/Outperform ratings after the Q1 beat-and-raise.
  • Citi also raised its Haemonetics target from $79 to $92 but kept a Neutral rating, flagging a more cautious stance on valuation.

Candlestick Chart

Live Update At 16:46:49 EDT: On Tuesday, August 18, 2026 Haemonetics Corporation stock [NYSE: HAE] is trending up by 15.77%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

HAE has shifted from a slow grinder to a momentum name on traders’ screens. After weeks grinding in the high-$70s to mid-$80s, Haemonetics broke out hard. From the 2026/07/24 close near $78.78, HAE pushed into the low-$90s by 2026/08/12, then exploded to a 2026/08/18 high of $106.67 before closing at $104.65.

That is a clear uptrend with higher highs and higher lows. The intraday tape on the latest session shows tight action between roughly $104 and $106, with repeated support around $104 and sellers appearing near $106.50. For short-term traders, HAE is acting like a strong, liquid breakout holding above prior resistance in the low-$90s.

More Breaking News

Under the hood, Haemonetics is not some story stock with no earnings. Q1 revenue came in at $339.4M and net income at about $33.0M. A roughly 59% gross margin, 7% net margin, and about 11%-12% pretax margin show a solid, profitable med-tech franchise. A price-to-sales around 3.1 and P/E near 44 tell traders the market is willing to pay up for this growth. Debt is meaningful, but coverage is strong and liquidity is solid, with a current ratio above 3.

Why Traders Are Watching HAE Momentum

Traders are crowding into HAE because the story lines up on three key fronts: earnings momentum, guidance, and Wall Street validation. First, the numbers. Haemonetics dropped a fiscal Q1 adjusted EPS print of $1.14 versus $0.87 expected. That is not a small beat. Revenue of $339.4M also topped the $327.9M consensus, telling traders the upside is being driven by real demand, not just cost cuts.

Management highlighted share gains in Plasma, continued strength in Blood Management Technologies, and a return to growth in Interventional Technologies. When a med-tech name like Haemonetics fires on all cylinders across segments, traders pay attention. On top of that, the company raised full-year guidance and nudged FY27 revenue and EPS growth targets up to 5%-8% from 4%-7%. That is a measured bump, but it signals confidence that this is a durable growth runway, not a one-quarter fluke.

The Street piled on after the print. Bank of America took its Haemonetics target from $93 to $100 and reiterated a Buy after hosting the CEO, calling for best-in-class performance and a valuation re-rating by FY27. Raymond James went even further, hiking its Haemonetics target to $105 with an Outperform. Baird moved to $96, Barrington to $95, all with bullish calls, while BofA Securities and others now sit around a roughly $96.90 consensus.

Citi is the cautious voice in the room, lifting its Haemonetics target from $79 to $92 but staying Neutral. That nuance matters for traders: the story is strong, but valuation is no longer cheap. The brief premarket softness after the beat-and-raise shows some profit-taking and positioning, not a broken thesis.

Conclusion

For active traders tracking HAE, the setup is straightforward: strong fundamentals are now aligned with an aggressive, confirmed breakout on the chart. Haemonetics delivered a clean beat on both earnings and revenue, raised near-term and FY27 guidance, and showcased momentum across Plasma, Blood Management Technologies, and Interventional lines. The balance sheet still carries leverage, but analysts like Barrington explicitly point to improving profitability and room to reduce debt by fiscal 2027.

On the sentiment side, Haemonetics now has a cluster of higher targets from Bank of America, Raymond James, Baird, Barrington, and BofA Securities, with a consensus near the high-$90s and a bullish outlier at $105. Citi’s Neutral at a $92 target helps anchor the upper end of the risk/reward debate and keeps fast money from getting complacent. For short-term traders, that creates a band of expectations to trade against while HAE holds above former resistance in the low-$90s.

The key from here is discipline. If Haemonetics keeps executing toward that 5%-8% growth lane into FY27, the Street’s “valuation re-rating” narrative stays intact. If margins or growth slip, this premium multiple can compress in a hurry. As Tim Sykes likes to say, “Patterns repeat, but you still have to manage your risk — cut losses quickly, protect your account, and only ride momentum when the trend is truly on your side.” As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This trading-focused perspective underscores why risk management and position sizing remain critical even when a ticker is breaking out. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”